Liquidia (LQDA) CFO and COO Kaseta Michael Sells $539K of Stock

Michael Kaseta, the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation (LQDA), sold 18,938 shares on October 12, 2026. The total value of this sale was about $539,354, with each share priced at $28.48. This sale was part of a planned transaction, indicating it was likely arranged ahead of time.

Other Institutional Activity in Liquidia Corporation

Blackrock Inc. holds a significant position in Liquidia, owning 10,788,586 shares worth approximately $370.6 million, after increasing its stake by 5,299,329 shares. Farallon Capital Management LLC owns 8,365,038 shares valued at about $287.3 million but reduced its holdings by 290,837 shares. Caligan Partners, LP has maintained its position of 8,118,892 shares worth roughly $278.9 million. Vanguard Capital Management LLC added 212,206 shares, bringing its total to 3,139,183 shares valued at about $107.8 million.

Liquidia Corporation Stock Down 2.9%

As of October 16, 2026, Liquidia's stock was recently trading around $33.77, which is below its 50-day moving average of $61.62 and its 200-day average of $53.93. The stock is also well below its 52-week high of $93.61, sitting about 63.9% lower. This performance may raise concerns for investors as the stock continues to struggle against key benchmarks.

Recent Earnings

In its latest earnings report, Liquidia Corporation reported trailing twelve-month revenue of $450.9 million and an earnings per share (EPS) of $1.39. The company has shown remarkable growth, with a revenue growth rate of 1,842.7% year-over-year. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Liquidia Corporation

On October 12, 2026, several insiders sold shares of Liquidia Corporation. Along with Michael Kaseta, Chief Human Resource Officer Krepp Sarah sold 5,245 shares for $149,377.60, while Officer Dana Boyle sold 5,892 shares worth about $167,804, and Officer Sanjeev Khindri sold 1,101 shares valued at $31,356. All transactions occurred at the same price of $28.48 per share.

Analysts Set New Price Targets

On October 1, 2026, Raymond James downgraded Liquidia to an Outperform rating with a target price of $53.00, down from $106.00. BTIG also downgraded the stock to Neutral. Needham maintained a Buy rating with a target of $72.00, while Wells Fargo downgraded to Equal-Weight with a target of $30.00. The consensus among analysts is currently a Buy rating, with a mean price target of $54.38 based on eight analyst opinions.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company based in Morrisville, NC. It focuses on developing and commercializing treatments for rare cardiopulmonary diseases. Its lead product is YUTREPIA, an inhaled medication for pulmonary arterial hypertension and related conditions. The recent insider activity and share sales are noteworthy as they may reflect the company's current challenges and market performance.

Bottom Line

Investors should monitor Liquidia's upcoming earnings report on November 3, 2026, for further insights into its financial health and performance. The recent insider sales, particularly by executives like Kaseta, could indicate significant developments within the company.